Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Moderate drinking may bolster our immune system and help fight off infection: Study

Medical science has known for years that people who drink moderate amounts of alcohol actually have a reduced risk of death. In general, they are healthier and have better cardiovascular function that those who don't drink alcohol at all.

17 Dec 2013

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers from Echelon Biosciences, Inc. and collaborators from the University of Utah report the use of ATX-Red AR-2 as a new imaging agent that effectively illuminates tumors.

17 Dec 2013

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease.

17 Dec 2013

Researchers confirm link between contrast agent and abnormalities on brain MRI

For the first time, researchers have confirmed an association between a common magnetic resonance imaging (MRI) contrast agent and abnormalities on brain MRI, according to a new study published online in the journal Radiology. The new study raises the possibility that a toxic component of the contrast agent may remain in the body long after administration.

17 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Standardized research approaches needed for developing new treatments for neurofibromatosis

As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches—including outcome measures specific to NF—are needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has been published as a supplement to Neurology, the Official Journal of the American Academy of Neurology (AAN).

13 Dec 2013

Blows to head may affect the brain's white matter and cognition even without concussion

New research suggests that even in the absence of a concussion, blows to the head during a single season of football or ice hockey may affect the brain's white matter and cognition, or memory and thinking abilities. The study is published in the December 11, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology. White matter is brain tissue that plays an important role in the speed of nerve signals.

12 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University today announced they have entered into a five-year, $6.5 million research collaboration.

12 Dec 2013

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

The prevalence of chronic fatigue syndrome in children and the significant impairment it causes to their physical functioning, school attendance and performance, and extracurricular activities, are at the root of a new Chicago-based study led by DePaul University psychologist Leonard A. Jason.

11 Dec 2013

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

11 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1.

11 Dec 2013

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.

10 Dec 2013

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Avanir Pharmaceuticals, Inc. today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

10 Dec 2013

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

A team led by a longtime Oregon Health & Science University researcher has demonstrated in mice what could be a revolutionary new technique to cure a wide range of human diseases - from cystic fibrosis to cataracts to Alzheimer's disease - that are caused by "misfolded" protein molecules.

9 Dec 2013

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

In mice with a rodent form of multiple sclerosis (MS), vitamin D appears to block damage-causing immune cells from migrating to the central nervous system, offering a potential explanation for why the so-called "sunshine vitamin" may prevent or ease symptoms of the neurodegenerative disease, according to results of a study at Johns Hopkins.

9 Dec 2013

TB vaccine may help prevent multiple sclerosis

A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Moderate drinking may bolster our immune system and help fight off infection: Study

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Researchers confirm link between contrast agent and abnormalities on brain MRI

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Standardized research approaches needed for developing new treatments for neurofibromatosis

Blows to head may affect the brain's white matter and cognition even without concussion

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

GW Pharmaceuticals receives U.S. patent for treating glioma

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

TB vaccine may help prevent multiple sclerosis

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in